Intelsat Continues Investment in Global 5G Software-Defined Network with Acquisition of Two Software-Defined Satellites from Thales Alenia Space
Intelsat, operator of the world’s largest integrated satellite and terrestrial network, and Thales Alenia Space, Joint Venture between Thales (67%) and Leonardo (33%) have signed an agreement to build two software-defined satellites designed to advance Intelsat’s global fabric of software-defined GEO connectivity as part of its 5G software-defined network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005271/en/
The artist’s view represents the two Intelsat software-defined satellites, IS-41 and IS-44, with the corresponding antennas configuration. (courtesy: Thales Alenia Space).
The addition of the Thales Alenia Space software-defined satellites represents an essential advancement in Intelsat’s 5G software-defined network designed to enable greater agility, flexibility and orchestration across edge, satellite and core. Named Intelsat 41 (IS-41) and Intelsat 44 (IS-44), the two next-generation software-defined satellites are scheduled to be in service in 2025. They will join two Airbus constructed software-defined satellites, Intelsat 42 (IS-42) and Intelsat 43 (IS-43), announced January 8, 2021.
Intelsat 41 and Intelsat 44 will be based on the Thales Alenia Space’s innovative Space Inspire product line allowing seamless telecommunications mission and services reconfiguration, instant in-orbit adjustment to broadband connectivity demand, and superior video broadcasting performance while maximizing the effective use of the satellite resources.
“Intelsat’s standards-based, open-architecture network design facilitates the incorporation of the best technology at any given time, further bolstering network resiliency,” said Stephen Spengler, CEO of Intelsat. “With the addition of Intelsat 41 and Intelsat 44, in partnership with Thales Alenia Space, Intelsat will blanket the earth with software-defined satellites, progressing the world’s first global 5G software-defined network, designed to unify the global telecoms ecosystem.”
The contract enables the continued advancement of Intelsat’s planned global software-defined satellite-based network, adding high-speed dynamically-allocated connectivity across Africa, Europe, the Middle East and Asia for commercial and government mobility services and cellular backhaul.
“Our relationship with Intelsat has been so meaningful knowing that our attractive Space Inspire software-defined solution will contribute to the realization of Intelsat’s global 5G software-defined unified network,” said Hervé Derrey, CEO of Thales Alenia Space. “We are proud that our advanced satellite technology will play a significant role in Intelsat’s vision to reimagine the global telecoms ecosystem.”
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, governments and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com .
About Thales Alenia Space
Drawing on over 40 years of experience and a unique combination of skills, expertise and cultures, Thales Alenia Space delivers cost-effective solutions for telecommunications, navigation, Earth observation, environmental management, exploration, science and orbital infrastructures. Governments and private industry alike count on Thales Alenia Space to design satellite-based systems that provide anytime, anywhere connections and positioning, monitor our planet, enhance management of its resources, and explore our Solar System and beyond. Thales Alenia Space sees space as a new horizon, helping to build a better, more sustainable life on Earth. A joint venture between Thales (67%) and Leonardo (33%), Thales Alenia Space also teams up with Telespazio to form the parent companies’ Space Alliance, which offers a complete range of services.
Thales Alenia Space has around 7,700 employees in 10 countries with 17 sites in Europe and a plant in the U.S. www.thalesaleniaspace.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005271/en/
Contact information
Melissa Longo, Intelsat, +1 (240) 308-1881, melissa.longo@intelsat.com
Thales Alenia Space contact(s)
Sandrine Bielecki, +33 (0)4 92 92 70 94, sandrine.bielecki@thalesaleniaspace.com
Catherine des Arcis, +33 (0)6 78 64 63 97, catherine.des-arcis@thalesaleniaspace.com
Marija Kovac, +39 (0)6 415 129 91, marija.kovac-somministrato@thalesaleniaspace.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom